X-Rx, Inc., a privately held biotechnology company focused on applying its innovative drug development capabilities to the generation of novel small molecule therapeutics, today announced that it has completed IND-enabling studies with X-165, a potent orally available inhibitor of autotaxin, for the treatment of idiopathic pulmonary fibrosis (IPF)